Literature DB >> 1551875

The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides.

D Batinić1, F A Robey.   

Abstract

gp120 is the envelope glycoprotein found on the surface of human immunodeficiency virus type 1 (HIV-1), and it binds to human cell surface CD4 receptors to initiate the HIV-1 infection process. It is now well-established that synthetic peptides from the V3 region on gp120 elicit antibodies that block HIV-1 infection and HIV-1-mediated cell fusion. Here we show that synthetic peptides derived from similar V3 regions of several isolates of HIV-1 bind [3H]heparin, and we also demonstrate that [3H]heparin binds to recombinant gp120 IIIB. The binding could be blocked by unlabeled heparin, dextran sulfate, and by a highly anionic benzylated synthetic peptide derived from human CD4 (amino acids 81-92). The nonbenzylated peptides from the same region were considerably less active. Unlabeled heparin, dextran sulfate, and the CD4-derived peptides were able to compete with the binding of soluble gp120 to immobilized antibodies against fragments of the V3 from isolate IIIB, but they had no effect on the binding of gp120 to anti-peptide antibodies targeted against another unrelated region of gp120. Biotin conjugated to the benzylated CD4-peptide bound to gp120 and was blocked from this binding by anti-V3 antibodies. These results indicate that the three materials that have been demonstrated by others to block HIV-1 infection in vitro, sulfated polysaccharides, certain CD4-derived synthetic peptides, and anti-V3 antibodies, may be acting through a common mechanism that includes binding to the V3 region of gp120 on HIV-1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551875

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

2.  Two novel vaginal microbicides (polystyrene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly associated with bacterial vaginosis.

Authors:  Jose A Simoes; Diane M Citron; Alla Aroutcheva; Robert A Anderson; Calvin J Chany; Donald P Waller; Sebastian Faro; Lourens J D Zaneveld
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

3.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Distinguishing glucuronic from iduronic acid in glycosaminoglycan tetrasaccharides by using electron detachment dissociation.

Authors:  Jeremy J Wolff; Lianli Chi; Robert J Linhardt; I Jonathan Amster
Journal:  Anal Chem       Date:  2007-01-25       Impact factor: 6.986

6.  Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4.

Authors:  M Benkirane; M Hirn; D Carrière; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1.

Authors:  J P Moore
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

Review 8.  Protein-glycosaminoglycan interactions: infectiological aspects.

Authors:  D Sawitzky
Journal:  Med Microbiol Immunol       Date:  1996-02       Impact factor: 3.402

9.  Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.

Authors:  Weihong Lai; Li Huang; Phong Ho; Zhijun Li; David Montefiori; Chin-Ho Chen
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

10.  Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

Authors:  E A Berger; J R Sisler; P L Earl
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.